Date: 2013-11-04
Type of information: Initiation of the trial
phase: 1
Announcement: initiation of the trial
Company: Canbex Therapeutics (UK)
Product: VSN16R
Action mechanism:
Disease: multiple sclerosis
Therapeutic area: Autoimmune diseases - Neurodegenerative diseases
Country:
Trial
details: The first-in-man study of VSN16R will enrol a total of 72 healthy volunteers in a placebo-controlled, single ascending dose and multiple ascending dose design. The study is being carried out by the clinical research organisation Quintiles.
Latest
news: * 0n November 4th, 2013, Canbex Therapeutics has announced that it has commenced a Phase I clinical trial to assess the safety and tolerability in humans of VSN16R, its novel, orally active lead compound aimed at treating spasticity in people with multiple sclerosis. Initiation of the Phase I trial follows successful preclinical studies that have demonstrated the excellent safety, efficacy and tolerability of VSN16R.Canbex closed a £2.1m ($3.2m) funding round in April 2013, led by MS Ventures, the corporate venture capital arm of Merck KGaA, Darmstadt, Germany, and won a grant of £1.25 ($1.8m) from the UK government’s Technology Strategy Board in March 2013. Other investors in Canbex include the Wellcome Trust, the US National Multiple Sclerosis Society, University College London (UCL Business Ltd) and Esperante Ventures.
